Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: RXRX

Recursion Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for RXRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.00

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 13:43 UTC.

What Recursion Pharmaceuticals, Inc. does

Recursion is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to discover and develop new medicines. The company operates an integrated platform called the Recursion Operating System that combines biological data generation, AI-powered molecular design, and clinical development tools across its internal drug programs and strategic partnerships.

Summarized from Recursion Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.00
Debt/equity0.01

Revenue, margins & earnings

FY2021: net loss $186M on revenue $10M$10MFY2021FY2022: net loss $239M on revenue $40M$40MFY2022FY2023: net loss $328M on revenue $45M$45MFY2023FY2024: net loss $464M on revenue $59M$59MFY2024FY2025: net loss $645M on revenue $75M$75MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-07
  • 2026-10-07DirectorSale-25,000$125.0K
  • 2026-10-07DirectorStock Option (Right to Buy)Option exercise-25,000$55.5K
  • 2026-10-07DirectorSale-50,000$242.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Recursion Pharmaceuticals, Inc. do?

Recursion is a clinical-stage biotechnology company that uses artificial intelligence and machine learning to discover and develop new medicines.

When did RXRX last file with the SEC?

Recursion Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-10-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 13:43 UTC. This page is also available as JSON at /api/data?ticker=RXRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for RXRX and 5,000+ tickers.

Create a free account — keep RXRX
For your agent
GET /api/data?ticker=RXRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt